CHMP recommends approval of Lilly Baqsimi (glucagon) nasal powder for emergency treatment of severe hypoglycemia in diabeticpatients

Recently, eli Lilly, thegiant ofpharmaceutical(http:// in the United States, announced that the EuropeanMedicines(http://Administration (
HTTP://WWW.CHEMDRUG.COM/)medicines (http://product seqproduct(http://Committee (CHMP) recommended the approval of Baqimi (triglyceglugin) nasal powder for the emergency treatment of severe hypoglycemia in people with people 4 years and olderAbout Baqsimi
Baqsimi (Baqsimi) is a powder that is given through the nasal cavity and is placed in a disposable, ready-to-use sprayer, which can be given by the caregiver through the nasal cavity for use in patients experiencing severe hypoglycemiaPatients do not need to take deep breaths after administration, and can even be given in patients in comaThe efficacy and safety of Baqsimi's treatment of severe hypoglycemia were evaluated in 2 studies in 83 and 70 diabetic patients, respectively, comparing the blood glucose response of insulin-induced hypoglycemia with single-dose paracetry injection therapy with single-dose glucagon injection 　　The results showed that Baqsimi could raise blood sugar levels sufficiently Similar results were observed in a pediatric study of 48 patients with type 1 diabetes over the age of 4 　　The most common adverse reactions associated with Baqsimi in the study were nausea, vomiting, headache, upper respiratory irritation, wet eyes, redness and itching The side effects of Baqsimi are similar to those used with an injection of glucagon, and due to the different methods of administration, nasal and eye-related symptoms, such as wet eyes and nasal congestion, can also occur 　　Baqsimi's U.S drug label includes a warning message that caution should be used in patients with chronic fasting, adrenal insufficiency, or chronic hypoglycemia, as these conditions can lead to lower levels of glucose that can be released in the liver 　　It is important to note that Baqsimi cannot be used in patients with chromoblastoma (a rare adrenal tissue tumor) or islet tumor (a pancreatic tumor), nor can it be used in patients who are known to be allergic to glucagon or Baqsimi non-active ingredients, as this may lead to allergic reactions